Vyome Holdings Inc. Common Stock (HIND)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market offers a $13.8M market-cap clinical-stage biotech at $1.97 as of 2026-10-13. Vyome has nine employees and two topical candidates: VT-1953 in Phase 2 for bacterial conjunctivitis and VT-1908, an eye drop. That is an R&D option, not a business with a moat. Graham taught me to look for durable earnings and assets; here I see no earnings. The Peter Lynch category is none because the company lost money in each of the last four years. Filed results show that in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $26,955 and net loss was $685,556; in fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $31,591 and net loss was $962,910. In fiscal Q3 2025, the quarter ended 2025-09-30, revenue was $34,627 and net loss was $8.4M. For fiscal 2025, the year ended 2025-12-31, revenue was $319,714 and net loss was $10.3M, versus fiscal 2024, the year ended 2024-12-31, revenue of $8.0M and net loss of $1.4M. Sales have collapsed while losses persist. Trailing free cash flow is -$5.6M, a -40.3% FCF yield. FairStock's Altman Z-score is -8.65, deep distress territory, and Piotroski is 4/9. Its price-to-book is 2.29, but ROE is -999.17%, so book value is not producing returns. The only balance-sheet positive is D/E of 0.00, no debt. The price-to-earnings is -1.22, meaningless with negative earnings. FairStock Score is 28/100. Valuation cannot be anchored on earnings. This is a speculative pipeline bet: if Phase 2 data are positive, the option value could change dramatically; if not, continued cash burn likely means dilution or worse. I prefer businesses I can understand and value with numbers, not hope.

In plain English: Vyome is a tiny drug company with nine employees, testing experimental eye medicines for conditions like bacterial conjunctivitis. It has not made a profit in the last four years, its revenue is very small, and its losses continue, so the business looks weak. With the stock at $1.97 on 2026-10-13 and very little sales to support it, the price does not look cheap based on current numbers; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer